AB0744 A “lost-to-follow-up” autoantibody for the diagnosis of autoimmune disease: prevalence and clinical characteristics of anti-nor90/hubf positive patients

Abstract

BackgroundAnti-nuclear antibody (ANA) patterns in indirect immunofluorescence testing (IIF) have been valuable in the diagnosis of autoimmune diseases. A pattern of speckling with fluorescent mitotic dots is considered to represent autoantibodies against nucleolar organising regions (NORs). Anti-NOR90 antibodies target the human upstream binding factor (hUBF) which activates RNA polymerase I-activated ribosomal RNA transcription. They have been anecdotally associated with systemic sclerosis (SSc), Sjögren’s Syndrome (pSS) and rheumatoid arthritis (RA).ObjectivesTo analyse the prevalence and clinical characteristics of patients found to be anti-NOR90 positive by immunology at The Dudley Group NHS FT (DGH) which also serves Worcestershire Acute Hospitals NHS Trust (WAH).MethodsClinical letters and electronic patient records of anti-NOR90 positive patients identified in the DGH immunology laboratory between July 2016 and October 2017 were reviewed. Advice was sought regarding ethical approval and consent; this was deemed unnecessary for this clinical survey. Anonymized patient data was collected on Excel. Anti-NOR90 was tested for when the characteristic ANA pattern was observed and as part of an extended SSc blot (EUROLINE SSc (Nucleoli) profile (IgG) – EUROIMMUN).ResultsWe identified 11 anti-NOR90 positive patients among 8000 positive ANA results (estimated prevalence 0.0137%). Patient demographics, diagnoses and immunology are illustrated in table 1. Patients were in their vast majority female (10/11, 91%) and had a median age of 63 (IQR:53–74) years. The median anti-NOR90 titer was 111 (IQR:14–139) intensity units. 6/11 (54.5%) had a confirmed diagnosis of rheumatic disease. The most common clinical features were Raynaud’s phenomenon (63.6%), sicca symptomatology (36.4%) and polyarthritis (36.4%). Interstitial lung disease (ILD) and oesophageal dysmotility (OD) were predominant clinical features in two cases (SSc, pSS). In general, patients lacked skin involvement (scleroderma, telangiectasias, calcinosis).Abstract AB0744 – Table 1Demographic, clinical and immunological characteristics of anti-NOR90 positive patientsPatientAge/SexDiagnosisRheumatoid FactorANA titreANA patternanti-NOR90 titre 182/FSSc-weak positivemitotic dotspositive280/MpSS-1:320speckled mitotic dots11335/FUCTD-1:2560nucleolar with mitotic dots140463/FRA+weak positivemitotic dotspositive581/FBronchiectasis-1:1280speckled mitotic dots107618/FRaynaud’s-1:1280mitotic dots139768/FRaynaud’s-1:320nucleolar with mitotic dots130856/FUCTD+1:320mitotic dots11966/FRaynaud’s-negativenegative141053/FRaynaud’s/Crohn’s disease-1:1280nucleolar+homogenous with mitotis dots1511152/FPolyarthritis-weak positivemitotic dots111ConclusionsLiterature regarding anti-NOR90 auto-antibodies has been scarce and in the age of automated IIF ANA testing, it is plausible that their specific nucleolar pattern is frequently missed. In our survey, they were observed in the context of several rheumatic diseases and linked to Raynaud’s, sicca symptoms and polyarthritis. Studies in l...